The group has provided an update for trading in the six months to March, with the recent COVID-19 issues expected to have a material impact on short-term trading. Trading for FY 2020 is expected to be H2 weighted with more resilient performances in A&D and lifesciences. The group has a strong order book, with some orders in EU and US being pushed back in the near term. We reduce revenues by 10%, which has a drop through impact of 42% on profits and EPS. We also place our FY 2021 forecasts
